drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific monoclonal antibody; T‑cell engager)
drug_description
Anti-CD20 × anti-CD3 bispecific IgG T‑cell engager (REGN1979) that binds CD20 on B cells and CD3 on T cells to redirect cytotoxic T cells to kill malignant CD20+ B cells.
nci_thesaurus_concept_id
C119615
nci_thesaurus_preferred_term
Odronextamab
nci_thesaurus_definition
A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific anti‑CD20×CD3 monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, physically bridging T cells to malignant CD20+ B cells to trigger T‑cell activation and cytotoxic killing (perforin/granzyme) of the target B cells.
drug_name
Odronextamab
nct_id_drug_ref
NCT06091865